News

JID Journal Supplement: Tuberculosis Drug Development

Tuberculosis Drug Development: Towards a Critical Path for Developing New Regimes to Treat Tuberculosis

Volume 211 suppl 3 June 15, 2015

Click here for access to supplement

Articles:

  • Eric Nuermberger and Debra Hanna Assessing the Landscape of Tools and Approaches for Novel Tuberculosis Regimen Development J Infect Dis. (2015) 211 (suppl 3): S81-S82 doi:10.1093/infdis/jiv072
More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...